LuciElace 86 mg Tablet contains Elacestrant, a next-generation oral selective estrogen receptor degrader (SERD) developed for the treatment of hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer in adults. It is particularly indicated for patients whose disease has progressed following endocrine therapy. https://www.drugsgeneral.com/lucielace-86-mg-tablet/